Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Esketamine nasal spray was recently approved for treatment-resistant depression. The current analysis evaluated the impact of symptom-based treatment frequency changes during esketamine treatment on clinical outcomes.
Methods: This is a post-hoc analysis of an open-label, long-term (up to 1 year) study of esketamine in patients with treatment-resistant depression (SUSTAIN 2). During a 4-week induction phase, 778 patients self-administered esketamine twice weekly plus a new oral antidepressant daily. In responders (≥50% reduction in Montgomery-Åsberg Depression Rating Scale total score from baseline), esketamine treatment frequency was thereafter decreased during an optimization/maintenance phase to weekly for 4 weeks and then adjusted to the lowest frequency (weekly or every other week) that maintained remission (Montgomery-Åsberg Depression Rating Scale ≤ 12) based on a study-defined algorithm. The relationship between treatment frequency and symptom response, based on clinically meaningful change in Clinical Global Impression-Severity score, was subsequently evaluated 4 weeks after treatment frequency adjustments in the optimization/maintenance phase.
Results: Among 580 responders treated with weekly esketamine for the first 4 weeks in the optimization/maintenance phase (per protocol), 26% continued to improve, 50% maintained clinical benefit, and 24% worsened. Thereafter, when treatment frequency could be reduced from weekly to every other week, 19% further improved, 49% maintained benefit, and 32% worsened. For patients no longer in remission after treatment frequency reduction, an increase (every other week to weekly) resulted in 47% improved, 43% remained unchanged, and 10% worsened.
Conclusions: These findings support individualization of esketamine nasal spray treatment frequency to optimize treatment response in real-world clinical practice.
Trial Registration: ClinicalTrials.gov identifier: NCT02497287.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387766 | PMC |
| http://dx.doi.org/10.1093/ijnp/pyaa027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Personalized Interactive Music Systems for Physical Activity and Exercise: Exploratory Systematic Review and Meta-Analysis.
JMIR Hum Factors
September 2025
Department of Music, Arts and Culture Studies, Centre of Excellence in Music, Mind, Body and Brain, University of Jyväskylä, Seminaarinkatu 15, Jyväskylän yliopisto, Jyväskylä, 40014, Finland, 358 6643034.
Background: Personalized Interactive Music Systems (PIMSs) are emerging as promising devices for enhancing physical activity and exercise outcomes. By leveraging real-time data and adaptive technologies, PIMSs align musical features, such as tempo and genre, with users' physical activity patterns, including frequency and intensity, enhancing their overall experience.
Objective: This exploratory systematic review and meta-analysis evaluates the effectiveness of PIMSs across physical, psychophysical, and affective domains.
Background: Oesophageal squamous cell carcinoma is the predominant histopathological subtype of oesophageal cancer across the world, representing as many as 90% of all cases; however, within Western cohorts, it is a low-prevalence disease, and, as such, appropriately powered trials to establish a standard treatment paradigm in this population remain challenging. The aim of this study was to assess current practices and compare outcomes for patients with locally advanced oesophageal squamous cell carcinoma across the UK and Ireland.
Methods: This was a retrospective multicentre cohort study of patients managed with curative intent for squamous cell carcinoma of the middle or distal oesophagus in 23 hospitals across the UK and Ireland.
Bayesian Counterfactual Machine Learning Individualizes Radiation Modality Selection to Mitigate Immunosuppression.
JCO Clin Cancer Inform
August 2025
Telperian, Austin, TX.
Purpose: Lymphocytes play critical roles in cancer immunity and tumor surveillance. Radiation-induced lymphopenia (RIL) is a common side effect observed in patients with cancer undergoing chemoradiation therapy (CRT), leading to impaired immunity and worse clinical outcomes. Although proton beam therapy (PBT) has been suggested to reduce RIL risk compared with intensity-modulated radiation therapy (IMRT), this study used Bayesian counterfactual machine learning to identify distinct patient profiles and inform personalized radiation modality choice.
View Article and Find Full Text PDF[The internal condom: overview, practical aspects and analysis of the barriers to its use].
Med Sci (Paris)
September 2025
Service de Gynécologie-Obstétrique, Hôpital Pitié-Salpêtrière, DMU ORIGYNE Femmes-Mères-Enfants, APHP, Paris, France - Sorbonne Université, Faculté de Santé, Paris, France.
The internal condom (commonly referred to as the female condom), which can be used by both men and women, is a single-use medical device that can be inserted several hours before sexual intercourse for the prevention of sexually transmitted infections (STIs) and for contraception. This review presents an overview of its use, and a summary of the technical and regulatory aspects. We will see that this device is almost as effective as its external counterpart and offers better protection against STIs, but that it remains very underused in the general population.
View Article and Find Full Text PDF[Transitioning to adult oncology for adolescents and young adults (AYAs): The experience of an AYA unit].
Med Sci (Paris)
September 2025
Département de cancérologie de l'enfant et l'adolescent (DCEA), Gustave Roussy cancer campus, Villejuif, France - Équipe mobile SPIAJA, équipe spécifique de prise en charge interdisciplinaire des adolescents et jeunes adultes, Gustave Roussy cancer campus, Villejuif, France.
Supporting the transition from pediatric to adult oncology presents challenges for all stakeholders, including adolescent and young adult (AYA) patients, their parents, pediatric oncologists, and medical oncologists. In this article, we describe the different stages of this transition and the transfer of care, the obstacles to the transition, and potential solutions. We discuss the contribution of AYA care in oncology through collaborations between pediatric and medical oncologists, and the importance of multidisciplinary support for patient empowerment.
View Article and Find Full Text PDF